Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $530 thousand versus the consensus estimate of $1.39 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.